title: Inhibitory effect of αS1- and αS2-casein hydrolysates on angiotensin I-converting enzyme in human endothelial cells in vitro, rat aortic tissue ex vivo, and renovascular hypertensive rats in vivo.
abstract: A great number of milk-derived peptides have been shown to exhibit angiotensin converting enzyme (ACE) inhibitory properties and thus potential utility in the regulation of blood pressure. The present work aimed to investigate the effects of 2 milk trypsin hydrolysates from alpha(S1)- and alpha(S2)-casein (CH1 and CH2, respectively) on ACE activity evaluated in human umbilical vein endothelial cells (HUVEC) in vitro, rat aortic tissues ex vivo, and renovascular hypertensive rat in vivo. Incubation of HUVEC and rat aortic tissues with CH1 or CH2 induced a concentration-dependent inhibition of hydrolysis of the ACE substrate hippuryl-histidyl-leucine (HHL), the hydrolysates being much less potent than perindopril (an ACE inhibitor). However, in contrast to perindopril, CH1 and CH2 failed to modify angiotensin I-induced aortic ring vasoconstriction. The HPLC profiles of rat plasma after intragastric administration were variable among individuals but none of the observed peaks corresponded to peptides comprising CH1 or CH2 or to fragments of these peptides. During 4 wk of cardiovascular monitoring, in hydrolysate-fed renovascular hypertensive rats, systolic blood pressure weakly decreased compared with the control group. However, the CH1-fed hypertensive rats exhibited a decrease of heart rate during the nocturnal period of activity. To conclude, our results show that CH1 and CH2 inhibited ACE activity in HUVEC and rat aortic tissue but failed to antagonize the aortic-constricting effects of the natural agonist angiotensin I. Moreover, we demonstrated that CH1, to a greater extent than CH2, can slightly affect cardiovascular parameters although the ingested bioactive peptides could not be detected in the blood.
authors.affiliation: INRA, Unité Mixte de Recherche 1154 INRA-Université Paris-Sud 11, Laboratoire Lipides membranaires et régulations fonctionnelles du coeur et des vaisseaux, Châtenay-Malabry, F-92296 France. delphine.rousseau@jouy.inra.fr
authors.forename: D
authors.initials: D
authors.lastname: Rousseau-Ralliard
authors.forename: F
authors.initials: F
authors.lastname: Goirand
authors.forename: S
authors.initials: S
authors.lastname: Tardivel
authors.forename: A
authors.initials: A
authors.lastname: Lucas
authors.forename: F
authors.initials: F
authors.lastname: Algaron
authors.forename: D
authors.initials: D
authors.lastname: Mollé
authors.forename: V
authors.initials: V
authors.lastname: Robert
authors.forename: D
authors.initials: D
authors.lastname: Auchère
authors.forename: J-F
authors.initials: JF
authors.lastname: Boudier
authors.forename: J-L
authors.initials: JL
authors.lastname: Gaillard
authors.forename: V
authors.initials: V
authors.lastname: Monnet
authors.forename: J
authors.initials: J
authors.lastname: Tauzin
authors.forename: A
authors.initials: A
authors.lastname: Grynberg
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D002364:Caseins / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000187:drug effects*; D006801:Humans; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002364:Caseins; C475729:casein hydrolysate; D007703:Peptidyl-Dipeptidase A